Neurocrine BiosciencesNBIX
NBIX
About: Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
Employees: 1,800
0
Funds holding %
of 7,139 funds
0
Analysts bullish %
of 10 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
48% more first-time investments, than exits
New positions opened: 105 | Existing positions closed: 71
20% more funds holding in top 10
Funds holding in top 10: 10 [Q3] → 12 (+2) [Q4]
18% more capital invested
Capital invested by funds: $10.9B [Q3] → $12.8B (+$1.98B) [Q4]
2% more funds holding
Funds holding: 563 [Q3] → 575 (+12) [Q4]
9% more call options, than puts
Call options by funds: $48M | Put options by funds: $44.2M
3% more repeat investments, than reductions
Existing positions increased: 208 | Existing positions reduced: 201
0.36% less ownership
Funds ownership: 93.29% [Q3] → 92.93% (-0.36%) [Q4]
Research analyst outlook
10 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$147
22%
upside
Avg. target
$167
38%
upside
High target
$185
53%
upside
10 analyst ratings
9 positive
90%
1 neutral
10%
0 negative
0%
HC Wainwright & Co. Andrew Fein 36% 1-year accuracy 125 / 348 met price target | 53%upside $185 | Buy Reiterated | 21 Feb 2025 |
Guggenheim Yatin Suneja 33% 1-year accuracy 8 / 24 met price target | 35%upside $163 | Buy Maintained | 10 Feb 2025 |
RBC Capital Brian Abrahams 16% 1-year accuracy 13 / 79 met price target | 23%upside $148 | Sector Perform Maintained | 7 Feb 2025 |
Wedbush Laura Chico 26% 1-year accuracy 15 / 57 met price target | 22%upside $147 | Outperform Maintained | 7 Feb 2025 |
Canaccord Genuity Sumant Kulkarni 36% 1-year accuracy 12 / 33 met price target | 35%upside $163 | Buy Maintained | 7 Feb 2025 |
Financial journalist opinion
Based on 15 articles about NBIX published over the past 30 days
Neutral
PRNewsWire
1 day ago
Neurocrine Biosciences Board of Directors Authorizes $500 Million Share Repurchase Program
SAN DIEGO , Feb. 21, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Board of Directors has authorized a new share repurchase program under which Neurocrine Biosciences may repurchase up to $500 million of its shares, subject to market conditions. This new share repurchase authorization is in addition to the $300 million accelerated repurchase program that was announced in October 2024 and completed in early February 2025.
Neutral
The Motley Fool
1 week ago
Why Neurocrine Biosciences Stock Sank Today
Despite better-than-expected profitability in the fourth quarter, which it reported late last week, Neurocrine Biosciences (NBIX -3.11%) hasn't been wowing analysts lately. On Monday, no less than three of them lowered their price targets on the biotech's shares, leaving them with a more than 3% loss in price on the day.
Neutral
Benzinga
2 weeks ago
Why Is Neurocrine Biosciences Stock Trading Lower On Friday?
On Thursday, Neurocrine Biosciences Inc. NBIX reported fourth-quarter adjusted EPS of $1.69, higher than the $1.54 reported a year ago, beating the consensus of $1.56.
Positive
The Motley Fool
2 weeks ago
Neurocrine Biosciences Reports Mixed Q4
Neurological therapeutics specialist Neurocrine Biosciences (NBIX -0.46%) reported mixed fourth-quarter earnings on Thursday, Feb. 6. Despite a slight miss on revenue expectations, its adjusted earnings per share (EPS) beat estimates significantly.
Neutral
Seeking Alpha
2 weeks ago
Neurocrine Biosciences, Inc. (NBIX) Q4 2024 Earnings Call Transcript
Neurocrine Biosciences, Inc. (NASDAQ:NBIX ) Q4 2024 Earnings Conference Call February 6, 2025 4:30 PM ET Company Participants Todd Tushla - Vice President of Investor Relations Kyle Gano - Chief Executive Officer Matt Abernethy - Chief Financial Officer Eric Benevich - Chief Commercial Officer Eiry Roberts - Chief Medical Officer Conference Call Participants Phil Nadeau - TD Cowen Paul Matteis - Stifel Tazeen Ahmad - Bank of America Akash Tewari - Jefferies Cory Kasimov - Evercore David Amsellem - Piper Sandler Malcolm Kuno - JPMorgan Chris Shibutani - Goldman Sachs Marc Goodman - Leerink Partners Jeffrey Hung - Morgan Stanley Charlie Moore - Baird Mohit Bansal - Wells Fargo Ash Verma - UBS Sumant Kulkarni - Canaccord Myles Minter - William Blair Laura Chico - Wedbush Securities Ami Fadia - Needham Uy Ear - Mizuho Malcolm Hoffman - BMO Capital Markets Operator Good day, everyone, and welcome to today's Neurocrine Biosciences Reports Q4 and Fiscal Year 2024 Earnings Call. [Operator Instructions] Please note today's call will be recorded, and I will be standing by should you need any assistance.
Negative
Zacks Investment Research
2 weeks ago
Neurocrine Biosciences (NBIX) Q4 Earnings and Revenues Lag Estimates
Neurocrine Biosciences (NBIX) came out with quarterly earnings of $1 per share, missing the Zacks Consensus Estimate of $1.56 per share. This compares to earnings of $1.44 per share a year ago.
Negative
Investors Business Daily
2 weeks ago
Neurocrine Crumbles On Lackluster Guidance For Its Bread-And-Butter Drug
Neurocrine stock took a hit late Thursday after the biotech company issued a light 2025 outlook for its drug, Ingrezza. The post Neurocrine Crumbles On Lackluster Guidance For Its Bread-And-Butter Drug appeared first on Investor's Business Daily.
Neutral
PRNewsWire
2 weeks ago
Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2024 Financial Results and Provides Financial Expectations for 2025
INGREZZA® (valbenazine) Fourth Quarter and Full Year 2024 Net Product Sales of $615 Million and $2.3 Billion, Representing Year-Over-Year Growth of 23% and 26% Respectively INGREZZA® (valbenazine) Full Year 2025 Net Product Sales Guidance of $2.5 - $2.6 Billion CRENESSITYTM (crinecerfont), a First-in-Class Treatment for Children and Adults with Classic Congenital Adrenal Hyperplasia, Approved and Launched in the United States Phase 3 Programs for Osavampator in Major Depressive Disorder and NBI-'568 in Schizophrenia Initiating in the First Half of 2025 SAN DIEGO , Feb. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the fourth quarter and full year ended December 31, 2024 and provided financial guidance for 2025. "I'm proud of the tremendous progress we made last year with the continued growth of INGREZZA for patients living with tardive dyskinesia or Huntington disease chorea.
Neutral
Zacks Investment Research
2 weeks ago
Neurocrine (NBIX) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Evaluate the expected performance of Neurocrine (NBIX) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Positive
Seeking Alpha
2 weeks ago
Neurocrine Biosciences Q4 Earnings Preview: What To Expect After The New Drug Approval
Neurocrine Biosciences stock is a buy due to robust sales growth, augmented by the FDA approval of CRENESSITY in December 2024. INGREZZA dominates current sales, but CRENESSITY, a new treatment for CAH, offers significant growth potential with first-year sales estimates of $150 million. Investors should expect volatility to accompany Q4 earnings and 2025 guidance, especially regarding CRENESSITY's initial sales figures. The earnings report is scheduled after-hours on Thursday.
Charts implemented using Lightweight Charts™